Issue 13 • Vol. 16 • 2025

Journal of Cancer

The study design of a phase 1b, dose-escalation study allowed early termination of each arm after initial results suggested unlikely clinical benefit



Cover feature: **Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma**

Ryan J. Sullivan, Katy K. Tsai, Anna C. Pavlick, Elizabeth I. Buchbinder, *et al.*

ISSN 1837-9664

9 771837 966005

IVYSPRING INTERNATIONAL PUBLISHER